© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
January 17, 2022
Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.
Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.
January 10, 2022
Focused discussion on the duration of maintenance avelumab for metastatic urothelial carcinoma and considerations for switching therapy.
A brief review of whether FGFR status in metastatic urothelial carcinoma should impact treatment approaches.
January 03, 2022
Shared insight on how best to discuss maintenance therapy with patients being treated for metastatic urothelial carcinoma.
Panelists consider whether the use of maintenance therapy is as prevalent after complete response or in patients with lesser PD-L1 expression.
December 21, 2021
Experts highlight the benefits of frontline avelumab maintenance therapy in patients with metastatic urothelial carcinoma.
Experts discuss frontline immunotherapy for metastatic urothelial carcinoma when chemotherapy may not be an option.
December 10, 2021
Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.
Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.